alexa Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Physicaltherapy & Rehabilitation

Physicaltherapy & Rehabilitation

Journal of Yoga & Physical Therapy

Author(s): Allegra CJ, Yothers G, OConnell MJ, Sharif S, Colangelo LH,

Abstract Share this page

Abstract PURPOSE: The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the safety and effectiveness of adding bevacizumab to modified infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) 6 regimen for the adjuvant treatment of patients with stage II or III colon cancer. We present safety information in advance of the planned analysis of efficacy. PATIENTS AND METHODS: Among 2,710 randomly assigned patients, demographic factors were balanced. Patients received modified FOLFOX6 every 2 weeks x 12 or modified FOLFOX6 plus bevacizumab (5 mg/kg every 2 weeks x 26, experimental group). RESULTS: Overall rates of grade 4 or 5 toxicities were nearly identical in the FOLFOX6 and FOLFOX6 plus bevacizumab arms (15.2\% and 15.0\%, respectively). Six-month mortality rates were 0.96\% and 0.90\% for the control and experimental groups, respectively. Grade 3+ toxicities that occurred more often in the experimental arm versus control arm included hypertension (12\% v 1.8\%, respectively), wound complications (abdominal incisional hernia or infusion port dehiscence/inflammation; 1.7\% v 0.3\%, respectively), pain (11.1\% v 6.3\%, respectively), and proteinuria (2.7\% v 0.8\%, respectively). Grade 2+ neuropathy was increased in the experimental arm versus the control arm (grade 2, 33\% v 29\%, respectively; grade 3, 16\% v 14\%, respectively; and grade 4, < 1\% each). In the experimental arm versus control arm, significantly less thrombocytopenia (1.4\% v 3.4\%, respectively) and fewer allergic reactions (3.1\% v 4.7\%, respectively) were observed. Advanced age was associated with a significantly greater rate of grade 4 and 5 toxicities regardless of treatment. CONCLUSION: Bevacizumab with modified FOLFOX6 is well tolerated in the surgical adjuvant setting in these patients. No significant increase in GI perforation, hemorrhage, arterial or venous thrombotic events, or death with the addition of bevacizumab to modified FOLFOX6 has been observed. Follow-up for potential delayed adverse effects and efficacy is ongoing.
This article was published in J Clin Oncol and referenced in Journal of Yoga & Physical Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords